利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.044 秒)

    Alanosine formulations and methods of use
    5.
    发明申请
    Alanosine formulations and methods of use 审中-公开
    阿诺糖苷配方及使用方法

    公开(公告)号：US20060041013A1

    公开(公告)日：2006-02-23

    申请号：US11153640

    申请日：2005-06-14

    申请人： Jason Brittain ,  Joe Franklin ,  Lorenzo Leoni ,  Christina Niemeyer ,  Gary Elliott

    发明人： Jason Brittain ,  Joe Franklin ,  Lorenzo Leoni ,  Christina Niemeyer ,  Gary Elliott

    IPC分类号： A61K31/21

    CPC分类号： A61K31/70 ,  A61K31/21 ,  A61K45/06 ,  A61K2300/00

    摘要： Stable liquid formulations of the anti-tumor agent L-alanosine are described. These formulations preferably comprise L-alanosine in an aqueous environment having a basic pH, preferably in the range of about pH 8-9. The alanosine formulations and compositions disclosed herein can be used for various purposes, including the treatment of various cancers, particularly those that are deficient in methylthioadenosine phophorylase (MTAP) enzymatic activity. Also described are methods for the treatment of diseases susceptible to treatment with alanosine, e.g., certain cancers, particularly those characterized by tumor cells that are MTAP deficient, wherein a patient is administered L-alanosine, alone or as part of a combination therapy with a second chemotherapeutic agent.

    摘要翻译： 描述了抗肿瘤剂L-肌氨酸的稳定的液体制剂。 这些制剂优选在具有碱性pH，优选在约pH8-9的范围内的水性环境中包含L-肌氨酸。 本文公开的肌苷制剂和组合物可以用于各种目的，包括治疗各种癌症，特别是那些缺乏甲基硫代腺苷磷酸化酶（MTAP）酶活性的那些。 还描述了用于治疗易于用阿那诺膦治疗的疾病的方法，例如某些癌症，特别是MTAP缺陷型肿瘤细胞特征的那些癌症，其中单独或作为联合治疗的一部分给予患者L-肌氨酸 第二化疗剂。

    Cancer treatments
    6.
    发明申请
    Cancer treatments 审中-公开
    癌症治疗

    公开(公告)号：US20060128777A1

    公开(公告)日：2006-06-15

    申请号：US11267010

    申请日：2005-11-04

    申请人： Heather Bendall ,  Gary Elliott ,  Lorenzo Leoni ,  Christina Niemeyer ,  Pratik Multani

    发明人： Heather Bendall ,  Gary Elliott ,  Lorenzo Leoni ,  Christina Niemeyer ,  Pratik Multani

    IPC分类号： A61K31/4184

    CPC分类号： A61K31/4184

    摘要： Methods and compositions for treating cancers characterized by death-resistant cancer cells are described. In general, such methods involve administration of a therapeutically effective amount of a compound that induces mitotic catastrophe in the some, and preferably most or all, of the cancerous cells. Methods for assessing the efficacy of such treatments are also provided.

    摘要翻译： 描述了以死亡抗性癌细胞为特征的治疗癌症的方法和组合物。 通常，这些方法包括给予治疗有效量的在一些，优选大多数或全部癌细胞中诱导有丝分裂突变的化合物。 还提供了评估这种治疗效果的方法。

    USE OF ETODOLAC TO TREAT HYPERPLASIA
    9.
    发明申请
    USE OF ETODOLAC TO TREAT HYPERPLASIA 审中-公开

    公开(公告)号：US20070299042A1

    公开(公告)日：2007-12-27

    申请号：US11615396

    申请日：2006-12-22

    申请人： Dennis Carson ,  Lorenzo Leoni ,  Mary Corr

    发明人： Dennis Carson ,  Lorenzo Leoni ,  Mary Corr

    IPC分类号： A61K31/407 ,  A61K31/496 ,  A61K31/56 ,  A61P35/00

    CPC分类号： A61K31/12 ,  A61K31/18 ,  A61K31/40 ,  A61K31/407 ,  A61K31/4745 ,  A61K31/496 ,  A61K31/50 ,  A61K31/56 ,  A61K31/675 ,  A61K31/7052

    摘要： The present invention provides a therapeutic method to treat non-malignant diseases characterized by the excessive tissue growth, e.g., hyperplastic diseases, comprising administering to a mammal (e.g., human) afflicted with excessive tissue growth, an effective amount of a derivative of an indole compound of formula (I):formula (I): wherein R1 is lower alkyl, (hydroxy)lower alkyl, lower alkenyl, lower alkynyl, lower cycloalkyl, phenyl, benzyl or 2-thienyl; R2, R3, R4 and R5 are the same or different and are each hydrogen or lower alkyl; each R6 is individually hydrogen, lower alkyl, hydroxy, (hydroxy)lower alkyl, lower alkoxy, benzyloxy, lower alkanoyloxy, nitro or halo, R7 is hydrogen, lower alkyl or lower alkenyl, X is oxy and thio, Y is carbonyl, —(CH2)1-3—, —(C1-C3)alkyl(CO)—, or —(CH2)1-3SO2—; Z is hydroxy, lower alkoxy, (C2-C4)acyloxy, —N(R8)(R9), phenylamino, (ω-(4-pyridyl)(C2-C4 alkoxy), (ω-((R8)(R9) amino)(C2-C4 alkoxy), an amino acid ester of (ω-(HO)(C2-C4))alkoxy, —N(R8)CH(R8)CO2H, 1′-D-glucuronyloxy, —SO3H, —PO4H2, —N(NO)(OH), —SO2NH2, —PO(OH)(NH2), —OCH2CH2N(CH3)3+, or tetrazolyl; wherein R8 and R9 are each H, (C1-C3)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R8), S or nonperoxide O; n is 0, 1, 2, or 3; wherein R8 and R9 are each H, (C1-C3)alkyl or together with N are a 5- or 6-membered heterocyclic ring comprising 1-3 N(R8), S or nonperoxide O; each alkyl or phenyl group of R1, R2, R3, R4,R5, R6, R7 and Z is optionally substituted with 1, 2, or 3 (C1-C4)alkyl groups; or a pharmaceutically acceptable salt thereof.